Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response.
OBJECTIVE
To report our experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for patients with metastatic renal cell carcinoma (mRCC).


METHODS
In our prospectively maintained tumor registry, we identified 6 mRCC patients with temsirolimus in >1st-line systemic therapy. Patients were followed by weekly clinical and laboratory examination during admission of temsirolimus. Re-staging with chest CT and abdominal MRI was performed every 3 months.


RESULTS
We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, pneumonitis was observed in 4 of 6 patients. Drug-related pneumonitis led to severe dyspnea, with the result that treatment with temsirolimus had to be interrupted for a short period of time in 2 patients and discontinued in 1 patient.


CONCLUSIONS
Temsirolimus proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of pneumonitis must not be underestimated.
Department of Urology, University of Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany. timur.kuru@med.uni-heidelberg.de
Timur Hasan
TH
Kuru
Johannes
J
Huber
Gencay
G
Hatiboglu
Nina
N
Wagener
Sascha
S
Pahernik
Boris
B
Hadaschik
Markus
M
Hohenfellner
D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D018572:Disease-Free Survival; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008495:Medical Oncology / Q000379:methods; D009362:Neoplasm Metastasis; D011014:Pneumonia / Q000139:chemically induced; D011446:Prospective Studies; D012042:Registries; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
C401859:temsirolimus; D020123:Sirolimus